Literature DB >> 26978214

Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.

John C Newman1, Michael A Steinman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26978214      PMCID： PMC5338944          DOI： 10.1001/jama.2015.18286

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

Authors:  Hillel S Panitch; Ronald A Thisted; Richard A Smith; Daniel R Wynn; James P Wymer; Anat Achiron; Timothy L Vollmer; Raul N Mandler; Dennis W Dietrich; Malcolm Fletcher; Laura E Pope; James E Berg; Ariel Miller
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  Copyright and Bedside Cognitive Testing: Why We Need Alternatives to the Mini-Mental State Examination.

Authors:  John C Newman
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

3.  Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Authors:  Jeffrey L Cummings; Constantine G Lyketsos; Elaine R Peskind; Anton P Porsteinsson; Jacobo E Mintzer; Douglas W Scharre; Jose E De La Gandara; Marc Agronin; Charles S Davis; Uyen Nguyen; Paul Shin; Pierre N Tariot; João Siffert
Journal:  JAMA       Date:  2015 Sep 22-29       Impact factor: 56.272

4.  Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.

Authors:  Erik P Pioro; Benjamin Rix Brooks; Jeffrey Cummings; Randolph Schiffer; Ronald A Thisted; Daniel Wynn; Adrian Hepner; Randall Kaye
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

5.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Authors:  B R Brooks; R A Thisted; S H Appel; W G Bradley; R K Olney; J E Berg; L E Pope; R A Smith
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910
  5 in total
  2 in total

1.  Prediction of Cardiovascular Risk to Guide Primary Prevention.

Authors:  Gregory D Curfman
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

2.  Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.

Authors:  Michael Fralick; Chana A Sacks; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2019-02-01       Impact factor: 21.873
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.